戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 es in diagnosis, treatment and management of portopulmonary hypertension.
2 liver disease was not related to the risk of portopulmonary hypertension.
3  therefore be integral to the development of portopulmonary hypertension.
4 confidence interval 0.09-0.65, P = 0.005) of portopulmonary hypertension.
5 d aerosolized epoprostenol in a patient with portopulmonary hypertension.
6 onary arterial hypertension in patients with portopulmonary hypertension.
7 cy and safety of macitentan in patients with portopulmonary hypertension.
8      We studied 15 consecutive patients with portopulmonary hypertension; 14 underwent acute administ
9                     Adults (>=18 years) with portopulmonary hypertension, a 6-minute walk distance of
10 re patients with structural cardiac disease, portopulmonary hypertension, acute variceal bleeding, an
11                                              Portopulmonary hypertension affects up to 6% of patients
12         Advances in diagnosis and therapy of portopulmonary hypertension allow patients with cirrhosi
13                 Hepatopulmonary syndrome and portopulmonary hypertension are two pulmonary vascular c
14 atients were receiving ongoing treatment for portopulmonary hypertension at the time of transplant.
15 rtal hypertension (hepatopulmonary syndrome, portopulmonary hypertension, cardiac dysfunction), and h
16                                              Portopulmonary hypertension, defined as mean pulmonary a
17 he transplanted cohort, 1-year survival from portopulmonary hypertension diagnosis date: 95.8%, 3-yea
18 increased pulmonary vascular resistance from portopulmonary hypertension, has been associated with in
19           New treatment modalities of severe portopulmonary hypertension have been introduced, and ma
20 t to determine the clinical risk factors for portopulmonary hypertension in patients with advanced li
21                        In moderate to severe portopulmonary hypertension, intravenous epoprostenol re
22 ng of portal hypertension is referred to as "portopulmonary hypertension." Intravenous epoprostenol (
23                                              Portopulmonary hypertension is a known complication in t
24                                              Portopulmonary hypertension is present in an estimated 5
25 criteria; II. Hepatopulmonary syndrome; III. Portopulmonary hypertension; IV. Implications for liver
26 ith severe long-term complications including portopulmonary hypertension, liver atrophy, hyperammonie
27                                              Portopulmonary hypertension may be screened with transth
28 c hydrothorax, hepatopulmonary syndrome, and portopulmonary hypertension, on post-LT survival, as wel
29 ly improved pulmonary vascular resistance in portopulmonary hypertension patients, with no hepatic sa
30 c shunts in patients with moderate or severe portopulmonary hypertension (POPH) and determined the as
31                                    Untreated portopulmonary hypertension (PoPH) carries a poor progno
32                                              Portopulmonary hypertension (PoPH) is a form of pulmonar
33                                              Portopulmonary hypertension (PoPH) is diagnosed in 2-6%
34                                              Portopulmonary hypertension (POPH) is the elevation of p
35                                              Portopulmonary hypertension (POPH) is the presence of pu
36 isorders, hepatopulmonary syndrome (HPS) and portopulmonary hypertension (POPH) may occur as a conseq
37                                              Portopulmonary hypertension (PoPH) occurs in roughly 5%
38           BMP9 levels were markedly lower in portopulmonary hypertension (PoPH) versus healthy contro
39                                              Portopulmonary hypertension (POPH) was previously associ
40                                              Portopulmonary hypertension (POPH), a form of pulmonary
41 aracterized: hepatopulmonary syndrome (HPS), portopulmonary hypertension (POPH), and hepatic hydrotho
42 clinical research: hepatopulmonary syndrome, portopulmonary hypertension (POPH), and hepatic hydrotho
43 ase (MELD) exception points to patients with portopulmonary hypertension (POPH), but potentially impo
44 of the liver transplant (OLT) candidate with portopulmonary hypertension (PPHTN) has dramatically cha
45 ension with portal hypertension, also called portopulmonary hypertension (PPHTN), is a known complica
46 g/min, for a 4-month period, after which the portopulmonary hypertension resolved and the patient und
47 and now report the first patient with severe portopulmonary hypertension successfully treated with ep
48 ale sex was associated with a higher risk of portopulmonary hypertension than male sex (adjusted odds
49                        A patient with severe portopulmonary hypertension was treated with intravenous
50 cular disease, congenital heart disease, and portopulmonary hypertension were analyzed with other pat
51 high risk of death in those with significant portopulmonary hypertension, where targeted medical ther
52 is were associated with an increased risk of portopulmonary hypertension, whereas hepatitis C infecti
53 irectly linked estrogen to increased risk of portopulmonary hypertension, whereas others implicate in
54 rm outcomes of patients with moderate-severe portopulmonary hypertension who were optimized with pulm
55 ecently reported the successful treatment of portopulmonary hypertension with chronic intravenous epo